Stocks and Investing Stocks and Investing
Mon, October 30, 2017

Matthew Luchini Maintained (BLUE) at Buy with Increased Target to $162 on, Oct 30th, 2017


Published on 2024-10-26 00:13:09 - WOPRAI, Matthew Luchini
  Print publication without navigation


Matthew Luchini of BMO Capital, Maintained "bluebird bio, Inc." (BLUE) at Buy with Increased Target from $134 to $162 on, Oct 30th, 2017.

Matthew has made no other calls on BLUE in the last 4 months.



There are 6 other peers that have a rating on BLUE. Out of the 6 peers that are also analyzing BLUE, 3 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Biren Amin of "Jefferies" Downgraded from Strong Buy to Hold on, Wednesday, October 11th, 2017
  • Vincent Chen of "Bernstein" Initiated at Hold and Held Target at $109 on, Thursday, July 27th, 2017
  • Dane Leone of "BTIG" Downgraded from Strong Buy to Hold on, Friday, June 30th, 2017


These are the ratings of the 3 analyists that currently disagree with Matthew


  • Josh Schimmer of "Evercore ISI Group" Upgraded from Hold to Buy on, Monday, October 16th, 2017
  • Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell on, Monday, October 2nd, 2017
  • Gena Wang of "Barclays" Initiated at Buy and Held Target at $151 on, Thursday, September 7th, 2017

Contributing Sources